✨ Free AI Report
Boiron Group (Boiron SA): Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Boiron Group (Boiron SA)
Company Research

Boiron Group (Boiron SA): Business Overview, Financials & Competitive Analysis

Boiron Group (Boiron SA) scores 6/10 on the AskCyborg Cyborg Score (Mixed). Mature market leader with strong profitability facing growth constraints; attractive valuation but limited upside potential. Boiron dominates the global homeopathy market with high margins and consistent profitability, but faces headwinds from modest revenue growth, margin compression from prior years, and declining sales momentum as alternative medicine adoption slows.

What is Boiron Group (Boiron SA)'s industry? Boiron Group (Boiron SA) (boiron.com) operates in Pharmaceuticals. AskCyborg classifies Boiron Group (Boiron SA) under Pharmaceuticals in its company registry.

Boiron is engaged in the manufacture and distribution of homeopathic preparations and is the world's leading company in its sector. Founded in 1932, the company operates globally with a significant presence across Eur...

6/ 10Mixed

Cyborg Score thesis

Mature market leader with strong profitability facing growth constraints; attractive valuation but limited upside...

Read the full analyst-debate transcript →
Industry Pharmaceuticals
2 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 7, 2026
AI-Verified Research
30+ Page Report

Get the Latest Boiron Group (Boiron SA) Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for Boiron Group (Boiron SA)

AskCyborg analysts argue the bull and bear cases for Boiron Group (Boiron SA) across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Boiron Group (Boiron SA) OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

Boiron Group (Boiron SA) Overview

Pro stress-test →

Boiron is engaged in the manufacture and distribution of homeopathic preparations and is the world's leading company in its sector. Founded in 1932, the company operates globally with a significant presence across Europe and international markets.

Strategic Profile

Pro stress-test →

In 2025, Boiron had annual revenue of 501.11M EUR with 2.78% growth, demonstrating modest stability in a mature market. The company maintained a gross profit margin of 73.6% in the most recent fiscal year, reflecting strong cost management in homeopathic product manufacturing and distribution.

Competitive Landscape

Pro stress-test →

Laboratoires Arkopharma and Teva Pharmaceutical Industries are competitors of Boiron. Boiron maintains the largest global share of the homeopathy market, but faces competition from generic homeopathic manufacturers and traditional pharmaceuticals. The market itself is challenged by regulatory scrutiny on homeopathy efficacy in developed markets.

Industry Context

Boiron Group (Boiron SA) operates in Pharmaceuticals.

Key facts

Founded: 1932 · Headquarters: Lyon, France · Employees: ~2,634 · Revenue: €501.11M (2025 annual) · Market cap: $566M

What the analysts stress-tested

The top findings that survived the multi-agent debate for Boiron Group (Boiron SA).

  • Global homeopathy market leader with ~€501M revenue as of 2025, but growth slowing to 2.78% year-over-year
  • In 2024, Boiron generated approximately €280M in turnover outside of France, indicating strong international diversification but with flat-to-negative growth trends
+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • February 2026Corporate deal with Panaxia Pharmaceutical Industries
  • 2025Annual revenue of €501.11M with 2.78% growth, representing deceleration from prior year
  • +1 moreTrack every material event for Boiron Group (Boiron SA) as it happens. Explore monitoring →
Get alerted when Boiron Group (Boiron SA) has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Homeopathic ProductsFrench homeopathic manufacturer→Pharmaceutical ProductsGeneric and specialty pharmaceuticals→

Compare Boiron Group (Boiron SA) with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Boiron Group (Boiron SA) operates in Pharmaceuticals. See how the rest of the sector scores on the Cyborg framework.

Browse Pharmaceuticals research →
NEW · MCP server

Ask your AI assistant about Boiron Group (Boiron SA)

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Boiron Group (Boiron SA) and its top competitor on Cyborg Score”
“What did Boiron Group (Boiron SA) do this quarter?”
“Is Boiron Group (Boiron SA) a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does Boiron Group (Boiron SA) do?+
Boiron is engaged in the manufacture and distribution of homeopathic preparations and is the world's leading company in its sector. Founded in 1932, the company operates globally with a significant presence across Eur...
What is Boiron Group (Boiron SA)'s Cyborg Score?+
Boiron Group (Boiron SA) has a Cyborg Score of 6/10 (Mixed). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Boiron Group (Boiron SA)'s main competitors?+
Named competitors include Homeopathic Products, Pharmaceutical Products. The full competitive landscape is in the AskCyborg report.
How can I get the full Boiron Group (Boiron SA) research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Boiron Group (Boiron SA) research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Boiron Group (Boiron SA) over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Pharmaceuticals research

Companies in the same sector and named competitors, ranked by Cyborg Score.

7Novartis AG7Recordati Industria Chimica e Farmaceutica SpA6CSPC Innovation Pharmaceutical Co., Ltd.